Following this program, participants should be able to:

Overall Congress Objectives
•   Summarize the current standards of oncology care, key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), and clinical research updates from the 2021 San Antonio Breast Cancer Symposium, and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer and improve patient outcomes.
•   Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.

Genetic/Familial Risk Assessment for Breast Cancer: Testing Considerations and Controversies
•   Recognize the utility of multigene testing for identification of high- and moderate-penetrance breast cancer susceptibility genes.
•   Review current genetic testing criteria for patients with breast cancer.
•   Identify when germline testing for the purpose of informing treatment decision-making in breast cancer is clinically indicated.

Impact of the Pandemic on Breast Cancer Screening
•   Recognize the challenges of breast cancer screening and diagnosis during the COVID-19 pandemic.
•   Describe how these challenges are expected to affect breast cancer-related morbidity and mortality and health disparities.
•   Identify measures that may be used to address knowledge gaps, to effectively resume breast cancer screening, and to mitigate breast cancer-related morbidity and mortality and health disparities.

Locoregional Management of Non-Metastatic Breast Cancer with SABCS Updates

Surgical Management of Non-Metastatic Breast Cancer with SABCS Updates
•   Individualize surgical management recommendations based on patient and tumor characteristics.
•   Develop an evidence-based approach for the surgical management of the axilla in patients with early stage breast cancer.
•   Discuss new and emerging data in the treatment of patients with early stage breast cancer and integrate key findings into clinical practice.

Radiation Therapy for Non-Metastatic Breast Cancer with SABCS Updates
•   Individualize radiation therapy recommendations based on patient and tumor characteristics.
•   Review optimal timing of radiation therapy for those receiving systemic adjuvant therapy.
•   Discuss data about new and emerging radiation treatment modalities in the treatment of patients with early stage breast cancer.

Neoadjuvant and Adjuvant Treatment for Breast Cancer with SABCS Updates

Neoadjuvant and Adjuvant Treatment for HER2-Negative Breast Cancer with SABCS Updates
•   Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage HER2-negative breast cancer.
•   Recognize key patient and clinical factors that influence selection of systemic adjuvant therapy for HER2-negative breast cancer.
•   Discuss clinical data of new and emerging supportive care interventions to improve quality of life of HER2-negative breast cancer patients undergoing neoadjuvant/adjuvant chemotherapy.

Neoadjuvant and Adjuvant Treatment for HER2-Positive Breast Cancer with SABCS Updates
•   Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage HER2-positive breast cancer.
•   Recognize key patient and clinical factors that influence selection of systemic neoadjuvant/adjuvant therapy for HER2-positive breast cancer.
•   Discuss clinical data of new and emerging supportive care interventions to improve quality of life of HER2-positive breast cancer patients undergoing neoadjuvant/adjuvant chemotherapy.

Management of Metastatic Breast Cancer with SABCS Updates

Management of HER2-Negative Metastatic Breast Cancer with SABCS Updates
•   Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR-positive, HER2-negative metastatic breast cancer.
•   List the current therapeutic approaches for management of metastatic triple negative breast cancer.
•   Outline new and emerging therapeutic options for patients with HER2-negative metastatic breast cancer.

Management of HER2-Positive Metastatic Breast Cancer with SABCS Updates
•   Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer.
•   Optimally manage common toxicities related to the HER2-targeted therapies.
•   Outline new and emerging therapeutic options for patients with HER2-positive metastatic breast cancer.

Managing Pain and Neuropathy in Breast Cancer Survivors
•   Discuss non-pharmacologic approaches to manage pain and chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors.
•   Compare and contrast the risks and benefits of the use of opioids in breast cancer survivors.
•   Define strategies to maintain patient safety and minimize the risks of opioid misuse and abuse during chronic opioid use.